Virologica Sinica

, Volume 31, Issue 5, pp 406–414 | Cite as

Ficolin-2 binds to HIV-1 gp120 and blocks viral infection

  • Fengling Luo
  • Tielong Chen
  • Jun Liu
  • Xihui Shen
  • Yinnan Zhao
  • Rongge Yang
  • Xiaolian Zhang
Research Article


Ficolin-2 is a lectin complement pathway activator present in normal human plasma and usually associated with infectious diseases, but little is known about the role of ficolin-2 in human immunodeficiency virus (HIV) infection. Here, we describe our novel findings that serum ficolin-2 concentrations of 103 HIV-1 patients were much higher compared to those of 57 healthy donors. In vitro analysis showed that HIV-1 infection could enhance ficolin-2 expression. We further demonstrated that recombinant ficolin-2 protein could bind with HIV-1 envelope glycoprotein gp120, and subsequently induce complement dependent cytotoxicity. Moreover, ficolin-2 could block the entry of HIV-1 into target cells (TZM-b1 and MT-2 cells) and infection in a ficolin-2 dosedependent manner. To our knowledge, this is the first report about the protective role of ficolin-2 against HIV-1 infection and our study suggests that ficolin-2 is an important human innate immune molecule against HIV.


ficolin-2 HIV-1 gp120 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Atkinson AP, Cedzynski M, Szemraj J, Swierzko A, Bak-Romaniszyn L, Banasik M, Zeman K, Matsushita M, Turner ML, Kilpatrick DC. 2004. L-ficolin in children with recurrent respiratory infections. Clin Exp Immunol, 138: 517–520.CrossRefPubMedPubMedCentralGoogle Scholar
  2. Chapman SJ, Vannberg FO, Khor CC, Segal S, Moore CE, Knox K, Day NP, Davies RJ, Crook DW, Hill AV. 2007. Functional polymorphisms in the FCN2 gene are not associated with invasive pneumococcal disease. Mol Immunol, 44: 3267–3270.CrossRefPubMedGoogle Scholar
  3. Chen T, Hu Y, Ding Q, Yu J, Wang F, Luo F, Zhang XL. 2015. Serum ficolin-2 concentrations are significantly changed in patients with hepatitis B virus infection and liver diseases. Virol Sin, 30: 249–260.CrossRefPubMedGoogle Scholar
  4. Dimitrov DS. 2000. Cell biology of virus entry. Cell, 10: 697–702.CrossRefGoogle Scholar
  5. Endo Y, Sato Y, Matsushita M, Fujita T. 1996. Cloning and characterization of the human lectin P35 gene and its related gene. Genomics, 36: 515–521.CrossRefPubMedGoogle Scholar
  6. Ezekowitz RAB, Kuhlman M, Groopman JE, Byrn RA. 1989. A human serum mannose-binding protein inhibits in vitro infection by the human immunodeficiency virus. J Exp Med, 169: 185–196.CrossRefPubMedGoogle Scholar
  7. Garred P, Larsen F, Seyfarth J, Fujita R, Madsen HO. 2006. Mannosebinding lectin and its genetic variants. Genes Immun, 7: 85e94.CrossRefGoogle Scholar
  8. Gilbert PB, McKeague IW, Eisen G, Mullins C, Guéye-NDiaye A, Mboup S, Kanki PJ. 2003. Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal. Stat Med, 22: 573–593.CrossRefPubMedGoogle Scholar
  9. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. 2009. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet, 373: 48–57.CrossRefPubMedGoogle Scholar
  10. Haurum JS, Thiel S, Jones IM, Fische PB, Laursen SB, Jensenius JC. 1993. Complement activation upon binding of mannanbinding protein to HIV envelope glycoproteins. Aids, 7: 1307–1313.CrossRefPubMedGoogle Scholar
  11. Hoffmann JA, Kafatos FC, Janeway Jr. CA, Ezekowitz RAB. 1999. Phylogenetic perspectives in innate immunity. Science, 284: 1313–1318.CrossRefPubMedGoogle Scholar
  12. Hummelshøj T, Thielens NM, Madsen HO, Arlaud GJ, Sim RB, Garred P. 2007. Molecular organization of human Ficolin-2. Mol Immunol, 44: 401–411.CrossRefPubMedGoogle Scholar
  13. Hu Q, Napier KB, Trent JO, Wang Z, Taylor S, Griffin GE, Peiper SC, Shattock RJ. 2005. Restricted Variable Residues in the Cterminal Segment of HIV-1 V3 Loop Regulate the Molecular Anatomy of CCR5 Utilization. J Mol Biol, 350: 699–712.CrossRefPubMedGoogle Scholar
  14. Ichijo H, Ronnstrand L, Miyagawa K, Ohashi H, Heldin CH, Miyazono K. 1991. Purification of transforming growth factorbeta 1 binding proteins from porcine uterus membranes. J Biol Chem, 266: 22459–22464.PubMedGoogle Scholar
  15. Keeffe JR, Gnanapragasam PNP, Gillespie SK, Yong J, Bjorkman PJ, Mayo SL. 2011. Designed oligomers of cyanovirin-N show enhanced HIV neutralization. P Natl Acad Sci USA, 108: 14079–14084.CrossRefGoogle Scholar
  16. Kilpatrick DC, McLintock LA, Allan EK, Copland M, Fujita T, Jordanides NE, Koch C, Matsushita M, Shiraki H, Stewart K, Tsujimura M, Turner ML. 2003. No strong relationship between mannan binding lectin or plasma ficolins and chemotherapyrelated infections. Clin Exp Immunol, 134: 279–284.CrossRefPubMedPubMedCentralGoogle Scholar
  17. Lars H, Tom E M, Thor U, Bjørn C, Pål A, Stig SF. 2003. Mannose-binding lectin in HIV infection: relation to disease progression and highly active antiretroviral therapy. JAIDS, 32: 354–361.Google Scholar
  18. Li GR, Liu J, Pan Q, Song ZB, Luo FL, Wang SR, Zhang XL, Zhou X. 2009. Synthesis and anti-HIV activity of [ddN]-[ddN] dimers and benzimidazole nucleoside dimers. Chem Biodivers, 6: 2200–2207.CrossRefPubMedGoogle Scholar
  19. Li Y, Cleveland B, Klots I, Travis B, Richardson BA, Anderson D, Montefiori D, Polacino P, Hu SL. 2008. Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol, 82: 638–651.CrossRefPubMedGoogle Scholar
  20. Liu J, Ali MA, Shi Y, Zhao Y, Luo F, Yu J, Xiang T, Tang J, Li D, Hu Q, Ho W, Zhang XL. 2009. Specifically binding of Lficolin to N-glycans of HCV envelope glycoproteins E1 and E2 leads to complement activation. Cell Mol Immunol, 6: 235–244.CrossRefPubMedPubMedCentralGoogle Scholar
  21. Liu Y, Endo Y, Iwaki D, Nakata M, Matsushita M, Wada I, Inoue K, Munakata M, Fujita T. 2005. Human M-ficolin is a secretory protein that activates the lectin complement pathway. J Immunol, 175: 3150–3156.CrossRefPubMedGoogle Scholar
  22. Lu J, Le Y. 1998. Ficolins and the fibrinogen-like domain. Immunobiology, 199: 190–199.CrossRefPubMedGoogle Scholar
  23. Lu J, Le Y, Kon OL, Chan J, Lee SH. 1996. Biosynthesis of human ficolin, an Escherichia coli-binding protein, by monocytes: Comparison with the synthesis of two macrophage-specific proteins, C1q and the mannose receptor. Immunology, 89: 289–294.CrossRefPubMedPubMedCentralGoogle Scholar
  24. Matsushita M, Endo Y, Taira S, Sato Y, Fujita T, Ichikawa N, Nakata M, Mizuochi T. 1996. A novel human serum lectin with collagen-and fibrinogen-like domains that functions as an opsonin. J Biol Chem, 271: 2448–2454.CrossRefPubMedGoogle Scholar
  25. Pan Q, Chen H, Wang F, Jeza ViT, Hou W, Zhao Y, Xiang T, Zhu Y, EndoY, Fujita T, Zhang XL. 2012. L-ficolin binds to glycoproteins HA and NA and inhibits influenza A virus infection both in vitro and in vivo. J Innate Immun, 4: 312–324.CrossRefPubMedGoogle Scholar
  26. Saarloos MN, Lint TF, Spear GT. 1995. Efficacy of HIV-specific and 'antibody-independent' mechanisms for complement activation by HIV-infected cells. Clin Exp Immunol, 99: 189–195.CrossRefPubMedPubMedCentralGoogle Scholar
  27. Sarma JV, Ward PA. 2011. The complement system. Cell Tissue Res, 343: 227–235.CrossRefPubMedGoogle Scholar
  28. Sugimoto R, Yae Y, Akaiwa M, Kitajima S, Shibata Y, Sato H, Hirata J, Okochi K, Izuhara K, Hamasaki N. 1998. Cloning and characterization of the Hakata antigen, a member of the ficolin/opsonin p35 lectin family. J Biol Chem, 273: 20721–20727.CrossRefPubMedGoogle Scholar
  29. Trujillo JR, Rogers R, Molina R M, Dangond F, McLane MF, Essex M, Brain JD. 2007. Noninfectious entry of HIV-1 into peripheral and brain macrophages mediated by the mannose receptor. Proc Natl Acad Sci USA, 104: 5097–5102.CrossRefPubMedPubMedCentralGoogle Scholar
  30. Tullis RH, Duffin RP, Handley HH, Sodhi P, Menon J, Joyce JA, Kher V. 2009. Reduction of hepatitis C virus using Lectin affinity plasmapheresis in dialysis patients. Blood Purificat, 27: 64–69.CrossRefGoogle Scholar
  31. Wyatt R, Sodroski J. 1998. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science, 280: 1884–1888.CrossRefPubMedGoogle Scholar
  32. Williams BG, Granich R, Dye C. 2011. Role of acute infection in HIV transmission. Lancet, 378: 1913.CrossRefPubMedGoogle Scholar
  33. Ying H, Ji X, Hart ML, Gupta K, Saifuddin M, Zariffard MR, Spear GT. 2004. Interaction of mannose-binding lectin with HIV type 1 is sufficient for virus opsonization but not neutralization. AIDS Res Hum Retroviruses, 20: 327–335.CrossRefPubMedGoogle Scholar
  34. Zhao Y, Ren Y, Zhang X, Zhao P, Tao W, Zhong J, Li Q, Zhang XL. 2014. Ficolin-2 inhibits Hepatitis C Virus infection, whereas apolipoprotein E3 mediates viral immune escape. J Immunol, 193: 783–796.CrossRefPubMedGoogle Scholar
  35. Zhang XL, Liu M, Xie P, Wan S, Yea JT, Zhou X, Wu J. 2004. Specific inhibition effects of N-pentafluorobenzyl-1-deoxynojirimycin on human CD4+ T cells. Bioorg Med Chem Lett, 14: 3789–3792.CrossRefPubMedGoogle Scholar

Copyright information

© Wuhan Institute of Virology, CAS and Springer Science+Business Media Singapore 2016

Authors and Affiliations

  1. 1.The State Key Laboratory of Virology, Department of Immunology and Hubei Province Key Laboratory of Allergy and Immune-related DiseasesWuhan University School of MedicineWuhanChina
  2. 2.Zhongnan Hospital of Wuhan UniversityWuhanChina
  3. 3.Wuhan Institute of VirologyChinese Academy of SciencesWuhanChina

Personalised recommendations